Alzheimer Disease

>

Latest News

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.
The Week in Review: March 11-15

March 16th 2024

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

FDA
Donanemab Delay: FDA Calls for Last-Minute Meeting to Discuss Safety and Efficacy

March 8th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

February 20th 2024

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.
The Week in Review: February 12-16

February 17th 2024

dementia
Drug for Agitation in Alzheimer Disease Dementia Fails in Phase 3 Trial

February 14th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.